An interesting Liau/Prins co-authored article particularly as we await news of the primary completion news (Primary Completion (Estimated) 2025-08-01) of the combo trial : Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
A Human Tumor-Immune Organoid Model of Glioblastoma : Shivani Baisiwala1#, Elisa Fazzari2 , Matthew X Li2 , Antoni Martija2 , Daria J Azizad2 , Lu Sun1 , Gilbert Herrera1 , Trinh Phan1 , Amber Monteleone1 , David A Nathanson3 , Anthony Wang1 , Won Kim1 , Richard G Everson1 , Kunal S Patel1 , Linda M Liau , Robert M Prins, Aparna Bhaduri2 June 20, 2025 "A major obstacle to identifying effective therapies for the aggressive brain tumor glioblastoma is the lack of human-specific, immunocompetent models that reflect the human tumor microenvironment. To address this, we developed the immune-Human Organoid Tumor Transplantation (iHOTT) model. This is an autologous co-culture platform that integrates patient-derived tumor cells and matched peripheral blood mononuclear cells (PBMCs) within human cortical organoids, enabling the study of the patient-specific immune response to the tumor and tumor-immune interactions. This platform preserves tumor and immune populations, immune signaling, and cell-cell interactions observed in patient tumors. Treatment of iHOTT with pembrolizumab, a checkpoint inhibitor, mirrored cell type shifts and cell interactions observed in patients. TCR sequencing further revealed pembrolizumab-driven expansion of stem-like CD4-T-cell clonotypes exhibiting patient-specific repertoires. These findings establish iHOTT as a physiologically relevant platform for exploring autologous tumor–immune interactions and underscore the critical need for antigen-targeted strategies to enhance immunotherapy in glioblastoma"
"These findings establish iHOTT as a physiologically relevant platform for exploring autologous tumor–immune interactions and underscore the critical need for antigen-targeted strategies to enhance immunotherapy in glioblastoma"
"While T cell-mediated approaches, including immune checkpoint inhibitors, DCVax, and CAR-T therapies, have shown significant promise in other cancers, there has been limited success with these strategies in glioblastoma (5). For example, only a small subset of patients show any objective response to checkpoint inhibition, and there is limited evidence as to what predicts response (6). Thus, models that faithfully preserve and permit manipulation of T cells as well as other immune cell types within the tumor context are urgently needed to accelerate therapeutic development"
An interesting Liau/Prins co-authored article particularly as we await news of the primary completion news (Primary Completion (Estimated) 2025-08-01) of the combo trial :
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible… pic.twitter.com/rrKBOZRGUT
Market Data 
Markets 
AI
